Herbal medicines to treat Alzheimer's disease

Trends in Pharmacological Sciences

Volumn 28, Issue 2, 2007, Pages 47-48

  Izzo, Angelo A ^a   Capasso, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBOXYLIC ACID DERIVATIVE; CITRAL; DNA FRAGMENT; GINKGO BILOBA EXTRACT; GINKGO BILOBA EXTRACT 761; MELISSA OFFICINALIS EXTRACT; PLACEBO; PLANT EXTRACT; ROSMARINIC ACID; SALVIA LAVANDULAEFOLIA EXTRACT; SALVIA OFFICINALIS EXTRACT; TERPENE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; BRADYCARDIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; LETTER; LIPID PEROXIDATION; MELISSA OFFICINALIS; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SALVIA; SALVIA LAVANDULAEFOLIA; SALVIA OFFICINALIS; SEIZURE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; GINKGO BILOBA; HUMANS; HUPERZIA; MELISSA; PHYTOTHERAPY; PLANT PREPARATIONS; SALVIA;

EID: 33846484330     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.12.001     Document Type: Letter

References (10)

1. Zhang H.Y., and Tang X.C. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci. 27 (2006) 619-625
2. Luo Y. Alzheimer's disease, the nematode Caenorhabditis elegans, and Ginkgo biloba leaf extract. Life Sci. 78 (2006) 2066-2072
3. Kurz A., and Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane Collaboration. Dement. Geriatr. Cogn. Disord. 18 (2004) 217-226
4. Hoerr R. Treatment effects of EGb 761 and cholinesterase inhibitors - why available studies do not demonstrate superiority of the latter. Phytomedicine 12 (2005) 598-600
5. Mazza M., et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol. 13 (2006) 981-985
6. Houghton P.J., and Howes M.J. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 14 (2005) 6-22
7. Iuvone T., et al. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-β peptide-induced neurotoxicity. J. Pharmacol. Exp. Ther. 317 (2006) 1143-1149
8. Akhondzadeh S., et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 28 (2003) 53-59
9. Perry N.S., et al. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol. Biochem. Behav. 75 (2003) 651-659
10. Akhondzadeh S., et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J. Neurol. Neurosurg. Psychiatry 74 (2003) 863-866